Pharma BD Deal Intelligence
Not actually an acquisition — a GSK cell-therapy licensing bet that GSK later reversed entirely, handing the asset back to Adaptimmune after exiting the modality
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Expanded agreement could yield ~$500M in NY-ESO development milestones; GSK effectively funds the pivotal synovial sarcoma studies and shares combination-study…
GSK and Adaptimmune expand their cancer immunotherapy collaboration, with up to eight proof-of-principle combination studies including checkpoint inhibitors…
GSK confirmed full transition of the NY-ESO SPEAR T-cell programme from Adaptimmune, taking sole responsibility for development and commercialization following…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Adaptimmune and GSK expanded their June 2014 strategic collaboration to accelerate development of NY-ESO SPEAR T-cell therapy toward registration trials in synovial sarcoma and exploration in MRCLS. Under the expanded terms, Adaptimmune was eligible for up to ~$500M in incremental development milestones for NY-ESO program alone if GSK exercised its option and successfully developed in multiple indications/HLA types. GSK retained option rights pending Phase 1 data review.
Not actually an acquisition — a GSK cell-therapy licensing bet that GSK later reversed entirely, handing the asset back to Adaptimmune after exiting the modality
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Adaptimmune Therapeutics plc / GlaxoSmithKline plc (this deal) | 2016 | $500M | 16 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2016 deals · Oncology deals